低钠血症如何诊治__培训课件.pptVIP

Discontinuation was mainly due to Infusion site reactions Other ADRs: hypotension, postural hypotension, pyrexia, hyperkalemia, infusion site thrombosis Prospective, multi-center, randomized centrally, double-blind, placebo controlled Conducted 2 trials to assess reproducibility (SALT-1 SALT-2) Tolvaptan 15mg tab 1 tab PO Daily x 30 days OR PBO Important Patient Population Criteria: Inclusion Etiologies: CHF, cirrhosis or SIADH Exclusion Criteria: Other etiologies Hypovolemic hyponatremia Other cardiac diseases (post-MI, SVT, SBP90) Serum Na 120 mmol/L w/ neurological impairment Poor prognos